Decreased production of endothelin-1 in asthmatic children after immunotherapy

Wu Yuan Chen, Joseph Yu, Jiu-Yao Wang

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Endothelin-1 (ET-1) is an endothelium-derived peptide that may be the most potent vasoconstrictor and bronchoconstrictor yet known. To investigate the role of ET-1 in the pathogenesis of bronchial asthma and the effect of immunotherapy (IT) on endothelin production, we measured the in vivo and in vitro production of ET-1 in 24 asthmatic children before and after specific allergen IT for 2 years as well as in age-matched healthy controls. Our results showed that both the plasma concentrations and in vitro production of ET-1 from the supernatants of cultured mononuclear cells (MNCs) were significantly higher in asthmatic children than in control subjects. The mean plasma levels of ET-1 in asthmatic children before or after IT were significantly higher than in controls (49.4 ± 26.5 and 30.6 ± 20.7 ng/L vs. 13.2 ± 8.5 ng/L, p < 0.05 and p < 0.01, respectively). When stimulated with phytohemagglutin (PHA) (1 μg/ml) or mite extract (10 μg/ml) for 3 days, mononuclear cells from asthmatic children before IT produced significantly higher ET-1 than did those after IT (31.8 ± 23.0 vs. 18.0 ± 15.7 ng/L, stimulated with mite, and 67.9 ± 22.4 vs. 25.0 ± 13.3 ng/L, stimulated with PHA). The decreased production of ET-1 in MNCs culture supernatant of asthmatic children after IT indicated that immunotherapy may result in an immune nonresponsive state, which may reverse the abnormal secretory pattern of ET-1 production in asthmatic children and partly account for its clinical effectiveness in treating atopic patients.

Original languageEnglish
Pages (from-to)29-35
Number of pages7
JournalJournal of Asthma
Volume32
Issue number1
DOIs
Publication statusPublished - 1995 Jan 1

Fingerprint

Endothelin-1
Immunotherapy
Mites
Bronchoconstrictor Agents
Immunologic Desensitization
Endothelins
Vasoconstrictor Agents
Endothelium
Cultured Cells
Asthma
Cell Culture Techniques
Peptides

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

@article{d4290b175cff403f8a2161da7c9b6910,
title = "Decreased production of endothelin-1 in asthmatic children after immunotherapy",
abstract = "Endothelin-1 (ET-1) is an endothelium-derived peptide that may be the most potent vasoconstrictor and bronchoconstrictor yet known. To investigate the role of ET-1 in the pathogenesis of bronchial asthma and the effect of immunotherapy (IT) on endothelin production, we measured the in vivo and in vitro production of ET-1 in 24 asthmatic children before and after specific allergen IT for 2 years as well as in age-matched healthy controls. Our results showed that both the plasma concentrations and in vitro production of ET-1 from the supernatants of cultured mononuclear cells (MNCs) were significantly higher in asthmatic children than in control subjects. The mean plasma levels of ET-1 in asthmatic children before or after IT were significantly higher than in controls (49.4 ± 26.5 and 30.6 ± 20.7 ng/L vs. 13.2 ± 8.5 ng/L, p < 0.05 and p < 0.01, respectively). When stimulated with phytohemagglutin (PHA) (1 μg/ml) or mite extract (10 μg/ml) for 3 days, mononuclear cells from asthmatic children before IT produced significantly higher ET-1 than did those after IT (31.8 ± 23.0 vs. 18.0 ± 15.7 ng/L, stimulated with mite, and 67.9 ± 22.4 vs. 25.0 ± 13.3 ng/L, stimulated with PHA). The decreased production of ET-1 in MNCs culture supernatant of asthmatic children after IT indicated that immunotherapy may result in an immune nonresponsive state, which may reverse the abnormal secretory pattern of ET-1 production in asthmatic children and partly account for its clinical effectiveness in treating atopic patients.",
author = "Chen, {Wu Yuan} and Joseph Yu and Jiu-Yao Wang",
year = "1995",
month = "1",
day = "1",
doi = "10.3109/02770909509089497",
language = "English",
volume = "32",
pages = "29--35",
journal = "Journal of Asthma",
issn = "0277-0903",
publisher = "Informa Healthcare",
number = "1",

}

Decreased production of endothelin-1 in asthmatic children after immunotherapy. / Chen, Wu Yuan; Yu, Joseph; Wang, Jiu-Yao.

In: Journal of Asthma, Vol. 32, No. 1, 01.01.1995, p. 29-35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Decreased production of endothelin-1 in asthmatic children after immunotherapy

AU - Chen, Wu Yuan

AU - Yu, Joseph

AU - Wang, Jiu-Yao

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Endothelin-1 (ET-1) is an endothelium-derived peptide that may be the most potent vasoconstrictor and bronchoconstrictor yet known. To investigate the role of ET-1 in the pathogenesis of bronchial asthma and the effect of immunotherapy (IT) on endothelin production, we measured the in vivo and in vitro production of ET-1 in 24 asthmatic children before and after specific allergen IT for 2 years as well as in age-matched healthy controls. Our results showed that both the plasma concentrations and in vitro production of ET-1 from the supernatants of cultured mononuclear cells (MNCs) were significantly higher in asthmatic children than in control subjects. The mean plasma levels of ET-1 in asthmatic children before or after IT were significantly higher than in controls (49.4 ± 26.5 and 30.6 ± 20.7 ng/L vs. 13.2 ± 8.5 ng/L, p < 0.05 and p < 0.01, respectively). When stimulated with phytohemagglutin (PHA) (1 μg/ml) or mite extract (10 μg/ml) for 3 days, mononuclear cells from asthmatic children before IT produced significantly higher ET-1 than did those after IT (31.8 ± 23.0 vs. 18.0 ± 15.7 ng/L, stimulated with mite, and 67.9 ± 22.4 vs. 25.0 ± 13.3 ng/L, stimulated with PHA). The decreased production of ET-1 in MNCs culture supernatant of asthmatic children after IT indicated that immunotherapy may result in an immune nonresponsive state, which may reverse the abnormal secretory pattern of ET-1 production in asthmatic children and partly account for its clinical effectiveness in treating atopic patients.

AB - Endothelin-1 (ET-1) is an endothelium-derived peptide that may be the most potent vasoconstrictor and bronchoconstrictor yet known. To investigate the role of ET-1 in the pathogenesis of bronchial asthma and the effect of immunotherapy (IT) on endothelin production, we measured the in vivo and in vitro production of ET-1 in 24 asthmatic children before and after specific allergen IT for 2 years as well as in age-matched healthy controls. Our results showed that both the plasma concentrations and in vitro production of ET-1 from the supernatants of cultured mononuclear cells (MNCs) were significantly higher in asthmatic children than in control subjects. The mean plasma levels of ET-1 in asthmatic children before or after IT were significantly higher than in controls (49.4 ± 26.5 and 30.6 ± 20.7 ng/L vs. 13.2 ± 8.5 ng/L, p < 0.05 and p < 0.01, respectively). When stimulated with phytohemagglutin (PHA) (1 μg/ml) or mite extract (10 μg/ml) for 3 days, mononuclear cells from asthmatic children before IT produced significantly higher ET-1 than did those after IT (31.8 ± 23.0 vs. 18.0 ± 15.7 ng/L, stimulated with mite, and 67.9 ± 22.4 vs. 25.0 ± 13.3 ng/L, stimulated with PHA). The decreased production of ET-1 in MNCs culture supernatant of asthmatic children after IT indicated that immunotherapy may result in an immune nonresponsive state, which may reverse the abnormal secretory pattern of ET-1 production in asthmatic children and partly account for its clinical effectiveness in treating atopic patients.

UR - http://www.scopus.com/inward/record.url?scp=0028956627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028956627&partnerID=8YFLogxK

U2 - 10.3109/02770909509089497

DO - 10.3109/02770909509089497

M3 - Article

VL - 32

SP - 29

EP - 35

JO - Journal of Asthma

JF - Journal of Asthma

SN - 0277-0903

IS - 1

ER -